908 Devices (908 Devices) Long-Term Capital Lease Obligation : $3.38 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is 908 Devices Long-Term Capital Lease Obligation?

908 Devices's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $3.38 Mil.

908 Devices's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 ($4.45 Mil) to Dec. 2023 ($3.93 Mil) and declined from Dec. 2023 ($3.93 Mil) to Mar. 2024 ($3.38 Mil).

908 Devices's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($4.51 Mil) to Dec. 2022 ($3.04 Mil) but then increased from Dec. 2022 ($3.04 Mil) to Dec. 2023 ($3.93 Mil).

908 Devices Long-Term Capital Lease Obligation Historical Data

The historical data trend for 908 Devices's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

908 Devices Long-Term Capital Lease Obligation Chart

908 Devices Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

6.94

5.84

4.51

3.04

3.93

908 Devices Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															5.46	4.96	4.45	3.93	3.38

908 Devices (NAS:MASS) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

908 Devices Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of 908 Devices's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

908 Devices (908 Devices) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » 908 Devices Inc (NAS:MASS) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

645 Summer Street, Boston, MA, USA, 02210

Website

https://www.908devices.com

908 Devices Inc manufactures medical devices. It has developed an innovative suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets.

Executives

Griffith Joseph H. Iv	officer: Chief Financial Officer	68 ELM STREET, HOPKINTON MA 01748
Christopher D. Brown	officer: Chief Technology Officer	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Kevin J. Knopp	director, officer: President and CEO	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Michael S. Turner	officer: VP, General Counsel	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Maura Fitzpatrick	officer: VP, Product Management & Mktg	908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Mark Spoto	director	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Michele Fournier	officer: Chief People Officer	908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Trent A. Basarsky	officer: Vice President, Commercial	C/O PROTEINSIMPLE, 3040 OAKMEAD VILLAGE DRIVE, SANTA CLARA CA 95051
John Kenneweg	officer: Vice President, Government	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Anthony Hunt	director	41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452
Nicolas Barthelemy	director	1750 BELLA LAGUNA CT, ENCINITAS CA 92024
Marcia Eisenberg	director	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Jeffrey P. George	director	C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Fenel M Eloi	director	C/O INTERLEUKIN GENETICS INC, 135 BEAVER STREET, WALTHAM MA 02452
Keith Crandell	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631